BACKGROUND: The central nervous system (CNS) is one of the most commonly involved sites in the systemic progression of primary @entity784 ( @entity784 ) such as @entity4888 ( @entity4888 ). There is no consensus on the treatment of CNS progression in CTCL, but survival of 3-6  months is suggested when @entity1499 -based chemotherapy and/or CNS irradiation is used. @entity2903 is active in earlier stages of @entity4888 and readily crosses the blood-brain barrier. There are no published data on its use in @entity4888 @entity1 with CNS involvement. METHODS: Four @entity4888 @entity1 were treated with oral @entity2903 (200  mg/m(2) per day for 5  d on a 28-day cycle) for CNS progression. Two @entity1 received @entity2903 with low-dose CNS irradiation as initial treatment, and two received @entity2903 following disease progression after @entity1499 -based chemotherapy and CNS irradiation. All @entity1 received @entity619 . RESULTS: @entity2903 was well tolerated; there were no treatment withdrawals or dose reductions caused by @entity137 . @entity1  1 had an excellent partial response in pre-irradiated disease. @entity1  2 showed disease stabilization following irradiation. @entity1  3 showed a complete response after a partial response to irradiation. @entity1  4 demonstrated continued stabilization after a partial response to irradiation. Overall survival ranged from 10 to 33  months. @entity1  3 remains alive and symptom-free at 23  months following treatment. CONCLUSIONS: @entity2903 following low-dose CNS irradiation appears to be well tolerated and effective in @entity4888 @entity1 with CNS progression. It may represent a less toxic alternative to chemotherapy containing @entity1499 or an option for second-line therapy.

@entity2903 for central nervous system involvement in XXXX .

@entity4888 :: ('MESH:D009182', 'Disease') :: ['mycosis fungoides', 'MF'] @entity1 :: ('9606', 'Species') :: ['patients', 'Patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity784 :: ('MESH:D016399', 'Disease') :: ['CTCLs', 'cutaneous T  cell lymphomas'] @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone'] @entity2903 :: ('MESH:C047246', 'Chemical') :: ['Temozolomide', 'temozolomide'] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate']
@entity4888 :: (MESH:D009182,Disease) :: ['mycosis fungoides']
